Name: Latest research reports of Ipca Laboratories Ltd. authored by Phillip Capital and published by - Trendlyne research reports.
Item: Ipca Laboratories Ltd.
Rating: 5
Author: Phillip Capital

Ipca Laboratories Ltd.

NSE: IPCALAB | BSE: 524494 | ISIN: INE571A01038 | Industry: Pharmaceuticals
| Mid-range Performer

1350.5000 2.10 (0.16%)

NSE Sep 25, 2025 15:31 PM

Volume: 106.0K

Ipca Laboratories Ltd.

11 Apr 2016

1350.50

0.16%

IPCA Co Update 11April2016

Buy: Ipca Laboratories Ltd.

Target

Phillip Capital

any volume of Artemisininbased Combination Therapy (ACTs) to IPCA, considering the continuingUSFDAimportbanonIPCA'splants.Wehadbuiltascenarioofnormalcyinthis supply,startingQ1FY17.Withnoorderallocation,IPCAwouldseeadverserevenueimpact...

Ipca Laboratories Ltd. has an average target of 1756.67 from 3 brokers.